WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will sponsor a dinner event during the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions at the Manchester Grand Hyatt in San Diego, California. Vascular robotics will be featured throughout the conference in the exhibit hall, presentations, and during the symposium. "Optimizing Care with CorPath GRX: Hot Topics in Robotic Interventions" will take place on Thursday, April 26, from 6:30 – 8:00 p.m. PST in room Harbor G. The symposium, chaired by Douglas Drachman, M.D. of Massachusetts General Hospital, will feature esteemed faculty Paul Campbell, M.D. of Carolinas HealthCare System NorthEast, William Lombardi, M.D. of the University of Washington, and Sunil Rao, M.D. of Duke University Medical Center. Presentations will highlight Rotate on Retract (RoR), the first smart procedural automation in the technIQ™ Series designed for the CorPath GRX platform. RoR allows the operator to quickly navigate to a targeted lesion by automatically rotating the guidewire upon joystick retraction, redirecting the tip for the next advancement.
Dr. Paul Campbell, Carolinas HealthCare System NorthEast, stated, "Rotate on Retract is proving to be a very useful and intuitive tool. During my first cases with RoR enabled, the predictable wire rotations assisted in navigating to difficult lesions and showed the potential to reduce procedure time. I look forward to sharing my clinical experience using RoR with my peers."
Space for the symposium is limited. For more information and to register for the symposium, please visit www.corindus.com/SCAI2018.
To take advantage of an exclusive opportunity to use the CorPath GRX System with an advanced simulator and smart procedural automation, register here and visit Corindus at booth #506.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.